WO2015095337A3 - Dérivés pyrazolo [1,5-a]pyrimidine carboxamide pour le traitement de troubles cognitifs - Google Patents

Dérivés pyrazolo [1,5-a]pyrimidine carboxamide pour le traitement de troubles cognitifs Download PDF

Info

Publication number
WO2015095337A3
WO2015095337A3 PCT/US2014/070876 US2014070876W WO2015095337A3 WO 2015095337 A3 WO2015095337 A3 WO 2015095337A3 US 2014070876 W US2014070876 W US 2014070876W WO 2015095337 A3 WO2015095337 A3 WO 2015095337A3
Authority
WO
WIPO (PCT)
Prior art keywords
pyrazolo
treating cognitive
cognitive impairment
pyrimidinecarboxamide derivatives
pyrimidinecarboxamide
Prior art date
Application number
PCT/US2014/070876
Other languages
English (en)
Other versions
WO2015095337A2 (fr
Inventor
Hyung Jin Ahn
J. Fraser Glickman
Sidney Strickland
Original Assignee
The Rockefeller University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Rockefeller University filed Critical The Rockefeller University
Publication of WO2015095337A2 publication Critical patent/WO2015095337A2/fr
Publication of WO2015095337A3 publication Critical patent/WO2015095337A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La présente invention concerne des composés de formule I et II: formule (I) ou formule (II) qui inhibent l'interaction entre le fibrinogène et l'amyloïde-β et qui sont utiles pour traiter les troubles cognitifs tels que la déficience de la mémoire et la maladie d'Alzheimer.
PCT/US2014/070876 2013-12-18 2014-12-17 Dérivés pyrazolo [1,5-a]pyrimidine carboxamide pour le traitement de troubles cognitifs WO2015095337A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361917648P 2013-12-18 2013-12-18
US61/917,648 2013-12-18

Publications (2)

Publication Number Publication Date
WO2015095337A2 WO2015095337A2 (fr) 2015-06-25
WO2015095337A3 true WO2015095337A3 (fr) 2015-11-12

Family

ID=53403877

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2014/070876 WO2015095337A2 (fr) 2013-12-18 2014-12-17 Dérivés pyrazolo [1,5-a]pyrimidine carboxamide pour le traitement de troubles cognitifs

Country Status (1)

Country Link
WO (1) WO2015095337A2 (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA52119A (fr) 2015-10-19 2018-08-29 Ncyte Corp Composés hétérocycliques utilisés comme immunomodulateurs
SG11201804152RA (en) 2015-11-19 2018-06-28 Incyte Corp Heterocyclic compounds as immunomodulators
EP4292650A3 (fr) 2015-12-22 2024-02-28 Incyte Corporation Composés hétérocycliques en tant qu'immunomodulateurs
AR108396A1 (es) 2016-05-06 2018-08-15 Incyte Corp Compuestos heterocíclicos como inmunomoduladores
WO2017205464A1 (fr) 2016-05-26 2017-11-30 Incyte Corporation Composés hétérocycliques utilisés comme immunomodulateurs
KR102685249B1 (ko) 2016-06-20 2024-07-17 인사이트 코포레이션 면역조절제로서의 복소환식 화합물
MA45669A (fr) 2016-07-14 2019-05-22 Incyte Corp Composés hétérocycliques utilisés comme immunomodulateurs
US20180057486A1 (en) 2016-08-29 2018-03-01 Incyte Corporation Heterocyclic compounds as immunomodulators
WO2018119221A1 (fr) 2016-12-22 2018-06-28 Incyte Corporation Dérivés pyridine utilisés en tant qu'immunomodulateurs
PL3558990T3 (pl) 2016-12-22 2022-12-19 Incyte Corporation Pochodne tetrahydroimidazo[4,5-c]pirydyny jako induktory internalizacji pd-l1
US20180179201A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Heterocyclic compounds as immunomodulators
US10308644B2 (en) 2016-12-22 2019-06-04 Incyte Corporation Heterocyclic compounds as immunomodulators
WO2019191707A1 (fr) 2018-03-30 2019-10-03 Incyte Corporation Composés hétérocycliques utilisés comme immunomodulateurs
DK3790877T3 (da) 2018-05-11 2023-04-24 Incyte Corp Tetrahydro-imidazo[4,5-c]pyridinderivater som pd-l1-immunmodulatorer
US11753406B2 (en) 2019-08-09 2023-09-12 Incyte Corporation Salts of a PD-1/PD-L1 inhibitor
KR20220075382A (ko) 2019-09-30 2022-06-08 인사이트 코포레이션 면역조절제로서의 피리도[3,2-d]피리미딘 화합물
BR112022009031A2 (pt) 2019-11-11 2022-10-11 Incyte Corp Sais e formas cristalinas de um inibidor de pd-1/pd-l1
TW202233615A (zh) 2020-11-06 2022-09-01 美商英塞特公司 Ｐｄ—１／ｐｄ—ｌ１抑制劑之結晶形式
WO2022099018A1 (fr) 2020-11-06 2022-05-12 Incyte Corporation Procédé de préparation d'un inhibiteur de pd-1/pd-l1
AU2021373044A1 (en) 2020-11-06 2023-06-08 Incyte Corporation Process for making a pd-1/pd-l1 inhibitor and salts and crystalline forms thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070082902A1 (en) * 2005-10-06 2007-04-12 Schering Corporation Pyrazolopyrimidines as protein kinase inhibitors
US20100305091A1 (en) * 2007-07-20 2010-12-02 Stanton Matthew G PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070082902A1 (en) * 2005-10-06 2007-04-12 Schering Corporation Pyrazolopyrimidines as protein kinase inhibitors
US20100305091A1 (en) * 2007-07-20 2010-12-02 Stanton Matthew G PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DATABASE PubChem 20 July 2009 (2009-07-20), Database accession no. 42877636 *
DATABASE PubChem 20 July 2009 (2009-07-20), Database accession no. AGN-PC-06CYCR *
DATABASE PubChem 22 June 2010 (2010-06-22), Database accession no. 07 MG 50 *
ZOU ET AL.: "Receptor tyrosine kinases positively regulate BACE activity and Amyloid-beta production through enhancing BACE internalization", CELL RESEARCH, vol. 17, 2007, pages 389 - 401, XP055237720, ISSN: 1001-0602 *

Also Published As

Publication number Publication date
WO2015095337A2 (fr) 2015-06-25

Similar Documents

Publication Publication Date Title
WO2015095337A3 (fr) Dérivés pyrazolo [1,5-a]pyrimidine carboxamide pour le traitement de troubles cognitifs
WO2016130920A3 (fr) Inhibiteurs de lrrk2 et leurs méthodes de production et d'utilisation
PH12019501321B1 (en) Use of pyrazolopyrimidine derivatives for the treatment of pi3k-delta related disorders
GEP20166554B (en) Nitrogenated heterocyclic compound
EP4321513A3 (fr) Composés de pyrrolotriazine en tant qu'inhibiteurs de tam
WO2017048702A8 (fr) Formes solides de dérivés d'isoquinolinone, leur procédé de fabrication, compositions les comprenant et méthodes d'utilisation de celles-ci
CA2871471C (fr) Inhibiteurs d'adn pk
WO2015010078A3 (fr) Composés hétéroaryles bicycliques substitués condensés en 6,5
WO2014106238A8 (fr) Composés hétérocycliques et leurs procédés d'utilisation
WO2013077921A3 (fr) Pyrazolo[3,4-d]pyrimidines substituées et utilisations de celles-ci
MX2015008957A (es) Fluoro-[1,3]oxazinas como inhibidores de beta-secretasa 1 (bace1).
IL235659A (en) History 3, 4 - Dihydro-h2 - Pyrido [1, 2 - a] Pyrazine – 1, 6 - Transformed deion used to treat (among other things) Alzheimer's disease
WO2015001504A3 (fr) Formulations d'anticorps et procédés correspondants
EP3307738A4 (fr) Aryl dihydro-2h-benzo[b][1,4]oxazine sulfonamide et composés apparentés destinés à être utilisés comme agonistes de ror et pour le traitement de maladies
WO2014022116A3 (fr) Composés de pyrazolone substituée et leurs procédés d'utilisation
NZ704863A (en) Bicyclic pyridinones useful as gamma secretase modulators
GEP20207172B (en) 1h-pyrazolo[4,3-b]pyridines as pde1 inhibitors
CA2929436C (fr) Composes, composition pharmaceutique et methodes a utiliser dans le traitement de maladies inflammatoires
WO2015110491A3 (fr) Dérivés de pyrazolo[1,5-a]pyrimidine -7-amine utiles en thérapie
NZ702254A (en) 5-amino[1,4]thiazines as bace 1 inhibitors
WO2015042414A8 (fr) Composés multicycliques et leurs procédés d'utilisation
WO2013083975A3 (fr) Nouveaux dérivés de pyrrole
WO2015066302A3 (fr) Compositions, méthodes d'utilisation et méthodes de traitement
WO2014035846A3 (fr) Composés azaindole substitué, leurs sels, leurs compositions pharmaceutiques et leurs procédés d'utilisation
AU2013208104A8 (en) Benzhydrol-pyrazole derivatives having kinase inhibitory activity and uses thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14871283

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 14871283

Country of ref document: EP

Kind code of ref document: A2